No long-term safety trial exists for injectable use
It seems that such a comparison might provide insights into how other cells in the body affect the immune system
To gain insights into the mechanism of VERO cell toxicity at high compound concentrations, the compounds were tested for inhibition of human cytoplasmic TrxR1 and GR
GPX4: Glutathione Peroxidase 4, GSH: glutathione, ROS: reactive oxygen species, IL-6: Interleukin-6, Interleukin-1 beta, TNF-: Tumor Necrosis Factor-alpha, MDA: malondialdehyde, TCL6: T-cell Leukemia/Lymphoma 6,TFRC: transferrin receptor, ALKBH5: AlkB Homolog 5, RNA, demethylase, FTL: ferritin light chain, SLC7A11: Solute Carrier Family 7 Member 11, ACSL4: Acyl-CoA, Synthetase Long Chain Family Member 4, HUVECs: Human Umbilical Vein Endothelial Cells, BaP: Benzo[a]pyrene, MARCHF1: Membrane Associated Ring-CH-Type Finger 1, VEGFA: Vascular Endothelial Growth Factor A, ANG-1: Angiopoietin-1, IGF2BP3: Insulin-like Growth Factor 2 mRNA-binding Protein 3, lnc-HZ06: Long Non-coding RNA HZ06, HIF1: Hypoxia-inducible Factor 1-alpha, NCOA4: Nuclear Receptor Coactivator 4, CRY2: Cryptochrome Circadian Regulator 2, BMAL1: Brain and Muscle ARNT-Like 1, TP53: Tumor Protein p53, EZH2: Enhancer of Zeste Homolog 2, TIMP1: Tissue Inhibitor of Metalloproteinases 1, SLC3A2: Solute Carrier Family 3 Member 2, GABARAPL2: GABA, Type A Receptor-Associated Protein Like 2, Fer-1: ferrostatin-1
